RecallRadar

FDA Drug recall D-1329-2022

Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured for: AvKARE, Inc

On 2022-08-17 the FDA classified a Class III recall of Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured for: AvKARE, Inc by Avkare, citing labeling: Label Error on Declared Strength.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1329-2022
ClassificationClass III
Statusterminated
Initiated2022-07-20
Published2022-08-17
Last updated2026-09-13 11:52 UTC
CompanyAvkare
DistributionUS

Product

Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-367-10, UPC 3 42291 36710 4

Reason

Labeling: Label Error on Declared Strength

Identifiers

upc342291367104
ndc42291-366-01
ndc42291-366-10
ndc42291-367-01
ndc42291-367-10
ndc42291-368-60
ndc42291-368-50
ndc42291-369-60
ndc42291-369-50
code_infoLot #: 42581 Exp. 12/2024; 42484 Exp. 11/2024; 41204 Exp. 05/2024; 38723 Exp. 02/2023; 37623 Exp. 10/2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1329-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.